Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have advanced, otherwise known as metastatic prostate cancer, and have exhausted conventional hormonal treatment plans may have a new option with the introduction of Pluvicto®, now available from the cancer experts at Karmanos Cancer Institute at McLaren Greater Lansing, in partnership with MSU Health Care.
“As the only cancer center in the mid-Michigan region to offer this therapy, we’re helping more men who are living with metastatic prostate cancer get alternative treatment without having to travel far,” said Dr. Daniel Isaac, hematologist and medical oncologist at MSU Health Care and at Karmanos Cancer Institute at McLaren Greater Lansing.
What is Pluvicto?
Pluvicto is a targeted therapy that delivers radiation treatment for someone with prostate cancer that has spread to other parts of the body. This FDA-approved treatment option has shown that it can delay the progression of the disease’s growth and works to reduce the size of the tumors as well.
“The therapy is done through infusion or an IV and is given up to six treatments,” said Dr. Isaac.
Who may benefit from Pluvicto?
“Patients with metastatic prostate cancer whose disease has progress on conventional hormone therapy and/or chemotherapy may benefit from this treatment,” said Dr. Isaac.
You may be eligible to receive Pluvicto treatment if your prostate cancer:
- Has not responded to other treatments
- Has spread to other parts of the body
If you or someone you know is battling prostate cancer and wondering if Pluvicto may be the next step in treatment options for you, please contact our oncology nurse navigator to learn more at (517) 975-7815.
To learn more about Karmanos Cancer Institute at McLaren Greater Lansing, click here.
For more articles on health and wellness, click here.